At Amnio Bio, our science is driven by a simple goal: to help the brain heal after stroke. Backed by more than 20 years of research, we are developing the world’s first anti-inflammatory and regenerative stroke therapy.
Unlike conventional stroke treatments that focus primarily on restoring blood flow, our approach is designed to reduce inflammation, support tissue repair, reduce the risk of infection and promote the brain’s healing process.
Amnio Bio’s therapy uses Human Amniotic Epithelial Cells (hAECs) to help reduce inflammation, support tissue repair, and promote recovery following stroke.
hAECs are delivered safely through a simple intravenous infusion.
Cells travel through the bloodstream and naturally target injured brain tissue.
hAECs help reduce inflammation and further damage and reduce the risk of infection.
Supporting tissue regeneration and improved neurological recovery.
A stroke occurs when blood flow to part of the brain is interrupted or a blood vessel ruptures, depriving brain tissue of oxygen and nutrients. Within minutes, brain cells begin to die, often leading to long-term disability or loss of function.
Stroke remains one of the leading causes of death and disability worldwide, affecting millions of people each year. Although emergency treatments have improved survival rates, there are no therapies available to help stop and repair damaged brain tissue after a stroke. Only Rehabilitation.
Amnio Bio’s therapy is based on Human Amniotic Epithelial Cells (hAECs), naturally occurring cells obtained from amniotic membranes of donated placentae after healthy births. These cells possess unique anti-inflammatory and regenerative properties that make them a promising candidate for stroke recovery.
Unlike many stem cell therapies, our treatment does not form tumours and does not require patients to take ongoing immunosuppressants.
